A recently reported series of tamoxifen‐melatonin conjugates (US Patent No. 08785501) hold promise against ER, HER2, triple‐negative, and tamoxifen‐resistant breast cancer cells (to be published). Here, ERBB2 is linked to breast carcinoma.